Agios Pharmaceuticals to present new data on mitapivat, tebapivat
Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in ...
ENDPOINTS NEWS52m
No­vo Nordisk takes For­ma’s sick­le cell treat­ment in­to Phase 3
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...
Zacks.com on MSN49m
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents ...
Investor's Business Daily on MSN55m
Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside'
Vertex beat third-quarter expectations late Monday, but an analyst says Vertex stock needs more "to drive another leg of stock upside." ...